Cagrisema is a potent new blend, a combination that integrates two peptides – cagrilintide and semaglutide.
Semaglutide is a GLP-1 receptor agonist; a version of human GLP-1 hormone, modified to resist the degradation by the enzyme dipeptidyl peptidase-4.
Cagrilintdide, on the other hand, is an amylin analogue. Its role is to mimic the human hormone amylin and is structurally designed to be resistant to enzymatic degradation.
Together, these two peptides profoundly influence chemical structures and induce hormonal changes:
- Leading to the receptor changes within the pancreas and the brain
- Boosting insulin secretion
- Interacting with the receptors involved in appetite regulation
- Mimicking the action of amylin
- Decreasing glucagon secretion
All in all, this is a sophisticated, more importantly, incredibly potent combination of two peptides whose actions complement each other. Cagrisema combination influences some key hormonal processes and plays a role in metabolic regulation.
Our support team is at your service, ensuring customer satisfaction.
